Name: Aroa Biosurgery (ARX) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

ARX

Pharmaceuticals, Biotechnology & Life Sciences

Aroa Biosurgery

Short interest: 0.00%; 0.00 pp 30d; as of 9 Oct 2026
Reported shorts: 471
Shares on issue: 345.903M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Aroa Biosurgery

AROA Biosurgery Limited specializes in regenerative healing products for soft-tissue repair. It emphasizes the use of extracellular matrix (ECM) biomaterials in its offerings, giving it a niche position in the medical devices market. The company aims to improve healing outcomes and reduce healthcare costs, standing out through its innovative solutions and successful commercialization strategies.

Company profile →

Aroa Biosurgery (ASX:ARX) has 0.00% of its shares on issue reported as short positions as of 9 Oct 2026, or about 471 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.47% in August 2023. ARX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads ARX today

Zanger BreakoutWatchScore 34rank 384 of 1942
CAN SLIMWatchScore 26rank 391 of 1541
Minervini Trend TemplateNot a candidate
Crowded-Short BreakoutNot a candidate
Quality compoundersWatchScore 10rank 1146 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

ARX fundamentals

In the year to 31 Mar 2026, Aroa Biosurgery (ASX:ARX) recorded revenue of NZ$103.9M and net profit after tax of NZ$4.7M. A year earlier it recorded revenue of NZ$84.7M and a net loss after tax of NZ$3.8M. Year-on-year growth: revenue +22.6% (FY). Net margin 4.5% (FY). Figures are in NZD, the company's reporting currency; source: ASX (Markit), as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →